Article
Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy
17 May 2023
Abstract excerpt
Recombinant adeno-associated virus (AAV) vectors have been, or are currently in use, in 332 phase I/II/III clinical trials in a number of human diseases, and in some cases, remarkable clinical efficacy has also been achieved. There are now three US Food and Drug Administration (FDA)-approved AAV "drugs," but it has become increasingly clear that the first generation of AAV vectors are not optimal. In addition,...
Topics
Join the communities discussing this publication.